Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 5
1994 2
1995 4
1996 2
1997 11
1998 13
1999 18
2000 8
2001 37
2002 43
2003 59
2004 71
2005 68
2006 97
2007 98
2008 104
2009 73
2010 69
2011 84
2012 70
2013 67
2014 57
2015 74
2016 93
2017 104
2018 109
2019 92
2020 107
2021 101
2022 113
2023 77
2024 100
2025 126
2026 40

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,940 results

Results by year

Filters applied: . Clear all
Page 1
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Hortobagyi GN, et al. Ann Oncol. 2018 Jul 1;29(7):1541-1547. doi: 10.1093/annonc/mdy155. Ann Oncol. 2018. PMID: 29718092 Free article. Clinical Trial.
The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respectively, and 54.5% versus 38.8%, respectively, for patients with measurable disease. ...CONCLUSIONS: The improved efficacy outcomes and managea …
The ORR was 42.5% versus 28.7% for all patients treated with ribociclib plus letrozole versus placebo plus letrozole, respecti …
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O'Shaughnessy J. Hortobagyi GN, et al. N Engl J Med. 2022 Mar 10;386(10):942-950. doi: 10.1056/NEJMoa2114663. N Engl J Med. 2022. PMID: 35263519 Clinical Trial.
BACKGROUND: In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal g …
BACKGROUND: In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longe …
Letrozole for Female Infertility.
Yang AM, Cui N, Sun YF, Hao GM. Yang AM, et al. Front Endocrinol (Lausanne). 2021 Jun 16;12:676133. doi: 10.3389/fendo.2021.676133. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34220713 Free PMC article. Review.
It has been more than 20 years since the initial clinical trial of letrozole for ovulation induction. In light of the accumulating clinical and basic evidence, the efficacy and safety of letrozole have been identified. This mini review focuses o …
It has been more than 20 years since the initial clinical trial of letrozole for ovulation induction. In light of the a …
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Ruhstaller T, et al. J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26. J Clin Oncol. 2019. PMID: 30475668 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus tamoxifen (either treatment received for 5 years) and their sequences (2 years of one treatment plus 3 years of the other) for postmenopausal …
PATIENTS AND METHODS: BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adjuvant letrozole versus ta …
Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.
Bansal S, Goyal M, Sharma C, Shekhar S. Bansal S, et al. Int J Gynaecol Obstet. 2021 Mar;152(3):345-350. doi: 10.1002/ijgo.13375. Epub 2020 Oct 14. Int J Gynaecol Obstet. 2021. PMID: 32920843 Clinical Trial.
METHODS: In this assessor blind, randomized controlled trial, 90 infertile women with PCOS were randomized to receive either letrozole or CC for ovulation induction in incremental doses for a maximum of three cycles. ...RESULTS: Mean endometrial thicknesses were 9.8 …
METHODS: In this assessor blind, randomized controlled trial, 90 infertile women with PCOS were randomized to receive either letro …
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Slamon DJ, Diéras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Slamon DJ, et al. J Clin Oncol. 2024 Mar 20;42(9):994-1000. doi: 10.1200/JCO.23.00137. Epub 2024 Jan 22. J Clin Oncol. 2024. PMID: 38252901 Free PMC article. Clinical Trial.
Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.PALOMA-2 demonstrated statistically and clinically significant improvement in progr …
Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, f …
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martínez-de Dueñas E, Amillano K, Di Cosimo S, Anton A, Cottu P, Shimizu E, Fernandez M, Sampayo-Cordero M, Cortés J; PARSIFAL-LONG Steering Committee and Trial Investigators. Llombart-Cussac A, et al. ESMO Open. 2025 Jul;10(7):105309. doi: 10.1016/j.esmoop.2025.105309. Epub 2025 Jun 17. ESMO Open. 2025. PMID: 40532361 Free PMC article.
Exploratory endpoints included identification of new clinical prognostic markers for OS, specifically PFS duration. RESULTS: A total of 419 of 486 (86.2%) patients from PARSIFAL were included. ...Efficacy results were consistent with those reported in the pivotal first-lin …
Exploratory endpoints included identification of new clinical prognostic markers for OS, specifically PFS duration. RESULTS: A total …
Comparison of Letrozole Versus Combination Letrozole and Clomiphene Citrate (CC) for Ovulation Induction in Sub Fertile Women with Polycystic Ovarian Syndrome (PCOS)-An Open Label Randomized Control Trial.
Sarkar S, Gupta N, Joseph T, Yadav B, Kunjummen AT, Kamath MS. Sarkar S, et al. Reprod Sci. 2024 Dec;31(12):3834-3842. doi: 10.1007/s43032-024-01743-0. Epub 2024 Nov 5. Reprod Sci. 2024. PMID: 39500849 Clinical Trial.
There was no significant improvement in ovulation, clinical pregnancy, or live birth rates with a combination of letrozole and CC versus letrozole alone in per woman randomized with PCOS. Trial RegistrationThe trial was prospectively registered …
There was no significant improvement in ovulation, clinical pregnancy, or live birth rates with a combination of letrozole and …
Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.
Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Franik S, et al. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4. Cochrane Database Syst Rev. 2022. PMID: 36165742 Free PMC article.
We also checked reference lists of relevant trials, searched the trial registers and contacted experts in the field for any additional trials. ...We included five additional trials for this update that now includes a total of 41 RCTs (6522 women). The …
We also checked reference lists of relevant trials, searched the trial registers and contacted experts in the field for any ad …
1,940 results